⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRNA News
Moderna, Inc. Common Stock
YieldMax® ETFs Announces Weekly Distributions for Group 2 ETFs
globenewswire.com
ARKK
TSLA
AAPL
NVDA
AMZN
META
GOOGL
NFLX
COIN
MSFT
DIS
XOM
JPM
AMD
PYPL
SQ
MRNA
AI
MSTR
SNOW
ABNB
BABA
TSM
SMCI
PLTR
MARA
CVNA
HOOD
BRK.B
DKNG
RBLX
RDDT
GME
HIMS
CRCL
GDX
mRNA Vaccines Market Forecast 2025-2032 | Industry to Double in Size | Regulatory Fast Track Approvals and Adaptive Licensing Frameworks Accelerating Next Generation mRNA Vaccines - ResearchAndMarkets.com
businesswire.com
PFE
MRNA
BNTX
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates
accessnewswire.com
MRNA
Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management
accessnewswire.com
MRNA
COVID-19 Diagnostic Research Report 2025: 5 Year Forecast by Technology, Product, Channel and Country, with Executive and Consultant Guides - ResearchAndMarkets.com
businesswire.com
ABT
AMGN
BDX
BIO
CERN
DGX
DHR
ENZ
EXAS
GILD
HHC
HOLX
ILMN
ISRG
JNJ
LH
LMT
MRNA
MYL
NBIX
NOC
NTRA
NVTA
ONVO
ORCL
PDD
PFE
QGEN
QRVO
REGN
RHHBY
RMD
ROST
SGEN
SIGA
SNPS
SPLK
SRPT
STEM
SYK
TCOM
TGT
TMO
TSLA
TXG
VRTX
WBA
XRAY
Immunoassay Market Research, Strategies, Trends and Forecasts Report 2025 with Executive Guides and Impact of Artificial Intelligence - ResearchAndMarkets.com
businesswire.com
ALGN
AMZN
BDX
BIO
BMY
CDNS
CERN
CHKP
CLVS
CODX
CRSP
CYTK
DELL
DGX
DHR
DIS
DTC
DXCM
ENZ
EXAS
FSLR
GILD
GOOG
IDXX
ILMN
INCY
INTC
ISRG
JNJ
LULU
LUMX
MDLZ
MRNA
MSFT
MYL
NBIX
NCLH
NFLX
NVS
NVTA
ORCL
ORGO
OSIP
OTIS
PANW
PFE
PG
PGR
PPC
PRGO
QCOM
QGEN
QORV
QUID
REGN
ROCH
ROST
SGEN
SIRI
SNPS
SPLK
SRPT
SWKS
SYK
TCOM
TEAM
TEVA
TGT
TMO
TSLA
TXN
ULTA
UNH
VRTX
WBA
WDC
WEC
WFC
XRAY
XTRA
ZBRA
Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities
accessnewswire.com
MRNA
Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025
accessnewswire.com
MRNA
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates
accessnewswire.com
MRNA
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma
accessnewswire.com
MRNA